Management of MAFLD (Metabolic-Associated Fatty Liver Disease)
Lifestyle modification with weight loss of 7-10% is the cornerstone of MAFLD management, combined with a Mediterranean diet, regular exercise (≥150 min/week moderate-intensity), and for patients with non-cirrhotic MASH and significant fibrosis (stage ≥2), resmetirom should be considered as MASH-targeted pharmacotherapy if locally approved. 1
Risk Stratification and Case-Finding
Start with a stepwise approach using non-invasive tests in high-risk populations:
- Target populations for screening: Patients with type 2 diabetes, obesity with additional metabolic risk factors, abnormal liver enzymes, or radiological signs of hepatic steatosis 1
- First step: Calculate FIB-4 (Fibrosis-4 index) to assess fibrosis risk 1
- Second step: Use transient elastography sequentially to rule-out/in advanced fibrosis, which predicts liver-related outcomes 1
This two-step approach is critical because advanced fibrosis is the strongest predictor of mortality and morbidity in MAFLD.
Lifestyle Interventions: The Foundation
Weight Loss Targets (Tiered by Goal)
For patients with overweight/obesity 2, 1:
- ≥5% weight loss: Reduces liver steatosis
- ≥7-10% weight loss: Improves liver inflammation (steatohepatitis) and fibrosis
- ≥10% weight loss: Maximal improvement in fibrosis
These are evidence-based thresholds with histological validation, not arbitrary targets.
Dietary Approach
Mediterranean diet is the most evidence-based dietary pattern 2, 1:
- Emphasize unprocessed/minimally processed foods: vegetables, fruits (not juice), low-fat dairy, nuts, olive oil, legumes, unprocessed fish and poultry
- Minimize processed meat, ultra-processed foods, and sugar-sweetened beverages
- Tailor to individual preferences and cultural context for sustainability
Physical Activity
≥150 minutes/week of moderate-intensity OR 75 minutes/week of vigorous-intensity physical activity 2, 1:
- Benefits occur even without weight loss
- Both aerobic and resistance training are effective
- Resistance training is particularly important for those losing weight to prevent sarcopenia
Alcohol and Smoking
- Alcohol: Discourage consumption; complete avoidance is mandatory in advanced fibrosis or cirrhosis 2
- Smoking: Cessation should be strongly encouraged regardless of fibrosis stage 3
Pharmacological Management
MASH-Targeted Therapy
Resmetirom is the first-line MASH-targeted therapy for eligible patients 1:
- Indication: Non-cirrhotic MASH with significant liver fibrosis (stage ≥2)
- Evidence: Demonstrated histological efficacy on steatohepatitis and fibrosis in Phase III trials with acceptable safety profile
- Critical limitation: If locally approved and dependent on label
No MASH-targeted pharmacotherapy is currently recommended for cirrhotic-stage disease 1
Metabolic Comorbidity Management
GLP-1 receptor agonists (semaglutide, tirzepatide) 1:
- Strong recommendation: Use for their approved indications (type 2 diabetes, obesity)
- Safe in MASH including compensated cirrhosis
- Improve cardiometabolic outcomes
- Substantial weight loss may provide hepatic histological benefit
SGLT2 inhibitors and metformin 1:
- Safe to use in MASLD
- Should be used for their respective indications (type 2 diabetes, heart failure, chronic kidney disease)
- Insufficient evidence as MASH-targeted therapies
Pioglitazone 1:
- Safe in non-cirrhotic MASH
- Cannot be recommended as MASH-targeted therapy due to lack of robust Phase III efficacy data
- May be used for diabetes management
What NOT to Use
Vitamin E: Cannot be recommended as MASH-targeted therapy despite some historical use, due to lack of robust Phase III demonstration and potential long-term risks 1
Nutraceuticals: Cannot be recommended due to insufficient evidence of effectiveness and safety 1
Bariatric Surgery
Consider for patients with MAFLD and obesity 1:
- Appropriate when lifestyle and medical interventions are insufficient
- Can achieve 20% body weight loss with improvement in diabetes control
- Effective for both hepatic and metabolic outcomes
Special Populations
Normal-Weight MAFLD
- Diet and exercise interventions still recommended to reduce liver fat 1
- Focus on diet quality improvement and physical activity
MASH Cirrhosis
Compensated cirrhosis with obesity 2, 1:
- Moderate weight reduction (3-5%)
- High-protein intake to prevent sarcopenia
- Maintain physical activity
Decompensated cirrhosis or sarcopenia 2, 1:
- High-protein diet
- Late-evening snack
- Nutritional counseling
- Surveillance for portal hypertension and HCC
- Liver transplantation evaluation
Multidisciplinary Approach
A coordinated multidisciplinary approach is essential 2, 1 because:
- MASLD has bidirectional connections with cardiometabolic comorbidities
- Cardiovascular disease is a leading cause of mortality in MAFLD patients
- Optimal management requires addressing both hepatic and extrahepatic outcomes
This includes hepatologists, endocrinologists, cardiologists, dietitians, and primary care physicians working together.
Monitoring and Follow-Up
Non-invasive tests may be used repeatedly 2, 1:
- Assess fibrosis progression in tailored fashion
- Provide limited information about treatment response at individual level
- Liver biopsy can be used in individual cases and clinical trials for monitoring
Key Clinical Pitfalls
- Don't wait for symptoms: MAFLD is typically asymptomatic until advanced stages
- Don't ignore cardiovascular risk: Cardiovascular disease, not liver disease, is often the primary cause of death
- Don't use resmetirom in cirrhotic patients: No evidence of benefit and not indicated
- Don't neglect fibrosis assessment: Fibrosis stage, not steatosis alone, determines prognosis
- Don't recommend vitamin E or nutraceuticals: Insufficient evidence and potential risks
The evidence strongly supports that preventing progression to cirrhosis through early intervention with lifestyle modification and appropriate pharmacotherapy in selected patients will reduce liver-related morbidity, mortality, and improve quality of life 1.